Brean Capital initiates coverage on Synta Pharma. (NASDAQ: SNTA) with a Buy. PT $12.00 saying they expect several important catalysts for lead drug candidate, Ganetespib, during 2013.
The firm comments, "We expect several important catalysts for SNTA's lead drug candidate, Ganetespib, during 2013 with important Phase 2 data readouts in lung and breast cancer. We forecast commercial launch of Ganetespib in 2015, with global sales in 2nd-line NSCLC alone reaching $1B by 2020. SNTA has initiated the pivotal Phase 3 portion of the GALAXY program for 2nd-line NSCLC, and we expect the trial to fully enroll by YE13, with an interim analysis during 1H14 and final results by 2H14. In the meantime, we expect the company to announce final PFS data for Ganetespib from the ongoing Phase 2b portion of the GALAXY program during 1H13, with overall survival from the trial maturing in 2H13."